© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 16, 1127-1135,
August 21, 1996
© 1996 Oxford University Press
Case—Control Study of Endogenous Steroid Hormones and Endometrial Cancer
Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics Bethesda, MD
Cancer Prevention Studies Branch, Division of Cancer Prevention and Control, National Cancer Institute Bethesda, MD
Department of Obstetrics and Gynecology, University of California at Irvine Medical Center
Department of Obstetrics and Gynecology, Milton S. Hershey Medical Center Hershey, PA
Department of Obstetrics and Gynecology, University of Minnesota Medical School Minneapolis
Department of Obstetrics and Gynecology, The Bowman Gray School of Medicine Winston-Salem, NC
Department of Obstetrics and Gynecology, Rush Medical College Chicago, IL
Division of Epidemiology-Biostatistics, School of Public Health, The University of Illinois Chicago
Department of Obstetrics and Gynecology, Northwestern University Medical School Chicago
Correspondence to: Nancy Potischman, Ph.D., National Institutes of Health, Executive Plaza North, Suite 443, Bethesda, MD 20892-7374.
BACKGROUND:: It has been suggested that identified risk factors for endometrial cancer operate through a single etiologic pathway, i.e., exposure to relatively high levels of unopposed estrogen (estrogen in the absence of progestins). Only a few studies, however, have addressed this issue directly.
PURPOSE:: We assessed the risk of developing endometrial cancer among both premenopausal and postmenopausal women in relation to the circulating levels of steroid hormones and sex hormone-binding globulin (SHBG). The independent effect of hormones was assessed after adjustment for other known risk factors.
METHODS:: The data used in the analysis are from a case—control study conducted in five geographic regions in the United States. Incident cases were newly diagnosed during the period from June 1, 1987, through May 15, 1990. The case patients, aged 20–74 years, were matched to control subjects by age, race, and geographic region. The community control subjects were obtained by random-digit-dialing procedures (for subjects 20–64 years old) and from files of the Health Care Financing Administration (for subjects 
65 years old). Additional control subjects who were having a hysterectomy performed for benign conditions were obtained from the participating centers. Women reporting use of exogenous estrogens or oral contraceptives within 6 months of interview were excluded, resulting in 68 case patients and 107 control subjects among premenopausal women and 208 case patients and 209 control subjects among postmenopausal women. The hormone analyses were performed on blood samples obtained from case patients or from hysterectomy control subjects before surgery. The odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by use of an unconditional logistic regression analysis after we controlled for matching variables and potential confounders. All P values were two-sided.
RESULTS:: High circulating levels of androstenedione were associated with 3.6-fold and 2.8-fold increased risks among premenopausal and postmenopausal women, respectively, after adjustment for other factors (P for trend =.01 and <.001, respectively). Risks related to other hormone fractions varied by menopausal status. Among postmenopausal women, a reduced risk was associated with high SHBG levels and persisted after adjustment was made for obesity and other factors (OR = 0.51; 95% CI = 0.27–0.95). High estrone levels were associated with increased risk (OR = 3.8; 95% CI = 2.2–6.6), although adjustment for other risk factors (particularly body mass index) diminished the effect (OR = 2.2; 95% CI = 1.2–4.4). Albumin-bound estradiol (E2), a marker of the bioavailable fraction, also remained an important risk factor after adjustment was made for other factors (OR = 2.0; 95% CI = 1.0–3.9). In contrast, high concentrations of total, free, and albumin-bound E2 were unrelated to increased risk in premenopausal women. In both premenopausal and postmenopausal groups, risks associated with obesity and fat distribution were not affected by adjustment for hormones.
CONCLUSION:: High endogenous levels of unopposed estrogen are related to increased risk of endometrial cancer, but their independence from other risk factors is inconsistent with being a common underlying biologic pathway through which all risk factors for endometrial cancer operate.
IMPLICATIONS:: Further research should focus on alternative endocrinologic mechanisms for risk associated with obesity and body fat distribution and for the biologic relevance of the increased risk associated with androstenedione in both premenopausal and postmenopausal disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Monge, E. Colas, A. Doll, A. Gil-Moreno, J. Castellvi, B. Diaz, M. Gonzalez, R. Lopez-Lopez, J. Xercavins, R. Carreras, et al. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress Carcinogenesis, August 1, 2009; 30(8): 1288 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fortuny, C. Sima, S. Bayuga, H. Wilcox, K. Pulick, S. Faulkner, A. G. Zauber, and S. H. Olson Risk of Endometrial Cancer in Relation to Medical Conditions and Medication Use Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1448 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Yang, M. Garcia-Closas, J. V. Lacey Jr., L. A. Brinton, J. Lissowska, B. Peplonska, S. Chanock, and M. M. Gaudet Genetic Variation in the Androgen Receptor Gene and Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 585 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Setiawan, J. A. Doherty, X.-o. Shu, M. R. Akbari, C. Chen, I. De Vivo, A. DeMichele, M. Garcia-Closas, M. T. Goodman, C. A. Haiman, et al. Two Estrogen-Related Variants in CYP19A1 and Endometrial Cancer Risk: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Howards, E. F. Schisterman, J. Wactawski-Wende, J. E. Reschke, A. A. Frazer, and K. M. Hovey Timing Clinic Visits to Phases of the Menstrual Cycle by Using a Fertility Monitor: The BioCycle Study Am. J. Epidemiol., January 1, 2009; 169(1): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Gargas, L. M. Sweeney, M. W. Himmelstein, L. H. Pottenger, J. S. Bus, and J. W. Holder Physiologically based Pharmacokinetic Modeling of Chloroethane Disposition in Mice, Rats, and Women Toxicol. Sci., July 1, 2008; 104(1): 54 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E Allen, T. J Key, L. Dossus, S. Rinaldi, A. Cust, A. Lukanova, P. H Peeters, N C. Onland-Moret, P. H Lahmann, F. Berrino, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) Endocr. Relat. Cancer, June 1, 2008; 15(2): 485 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Caserta, L. Maranghi, A. Mantovani, R. Marci, F. Maranghi, and M. Moscarini Impact of endocrine disruptor chemicals in gynaecology Hum. Reprod. Update, January 1, 2008; 14(1): 59 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Bakkum-Gamez, J. Gonzalez-Bosquet, N. N. Laack, A. Mariani, and S. C. Dowdy Current Issues in the Management of Endometrial Cancer Mayo Clin. Proc., January 1, 2008; 83(1): 97 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Monge, E. Colas, A. Doll, M. Gonzalez, A. Gil-Moreno, J. Planaguma, M. Quiles, M. A. Arbos, A. Garcia, J. Castellvi, et al. ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer Cancer Res., July 15, 2007; 67(14): 6753 - 6759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Tao, Q. Cai, Z.-F. Zhang, W.-H. Xu, N. Kataoka, W. Wen, Y.-B. Xiang, W. Zheng, and X. O. Shu Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 943 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Hecht and G. L. Mutter Molecular and Pathologic Aspects of Endometrial Carcinogenesis J. Clin. Oncol., October 10, 2006; 24(29): 4783 - 4791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sherman, J. V. Lacey, S. S. Buys, D. J. Reding, C. D. Berg, C. Williams, and P. Hartge Ovarian Volume: Determinants and Associations with Cancer among Postmenopausal Women. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1550 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Missmer, D. Spiegelman, E. R. Bertone-Johnson, R. L. Barbieri, M. N. Pollak, and S. E. Hankinson Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 972 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. Yumuk and P. F. Yumuk What Links Obesity to Cancer? Indoor and Built Environment, December 1, 2005; 14(6): 527 - 532. [Abstract] [PDF]
|
|
|
|
|
|
F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss Inflammation and Endometrial Cancer: A Hypothesis Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2840 - 2847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Bulun, Z. Lin, G. Imir, S. Amin, M. Demura, B. Yilmaz, R. Martin, H. Utsunomiya, S. Thung, B. Gurates, et al. Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment Pharmacol. Rev., September 1, 2005; 57(3): 359 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Napoli, S. Donepudi, S. Sheikh, G. B. Rini, and R. Armamento-Villareal Increased 2-Hydroxylation of Estrogen in Women with a Family History of Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2035 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Segawa, M. Shozu, K. Murakami, T. Kasai, K. Shinohara, K. Nomura, S. Ohno, and M. Inoue Aromatase Expression in Stromal Cells of Endometrioid Endometrial Cancer Correlates with Poor Survival Clin. Cancer Res., March 15, 2005; 11(6): 2188 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Xu, W. Zheng, Y. B. Xiang, Z. X. Ruan, J. R. Cheng, Q. Dai, Y. T. Gao, and X. O. Shu Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study BMJ, May 29, 2004; 328(7451): 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Lacey Jr., N. Potischman, M. P. Madigan, M. L. Berman, R. Mortel, L. B. Twiggs, R. J. Barrett, G. D. Wilbanks, J. R. Lurain, C.-M. Fillmore, et al. Insulin-Like Growth Factors, Insulin-Like Growth Factor-Binding Proteins, and Endometrial Cancer in Postmenopausal Women: Results from a U.S. Case-Control Study Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 607 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF]
|
|
|
|
|
|
R. Kaaks, A. Lukanova, and M. S. Kurzer Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1531 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rinaldi, A. Geay, H. Dechaud, C. Biessy, A. Zeleniuch-Jacquotte, A. Akhmedkhanov, R. E. Shore, E. Riboli, P. Toniolo, and R. Kaaks Validity of Free Testosterone and Free Estradiol Determinations in Serum Samples from Postmenopausal Women by Theoretical Calculations Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1065 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Anderson, E. Anderson, P. J. Mink, C. P. Hong, L. H. Kushi, T. A. Sellers, D. Lazovich, and A. R. Folsom Diabetes and Endometrial Cancer in the Iowa Women's Health Study Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Newcomb, A. Trentham-Dietz, K. M. Egan, L. Titus-Ernstoff, J. A. Baron, B. E. Storer, W. C. Willett, and M. J. Stampfer Fracture History and Risk of Breast and Endometrial Cancer Am. J. Epidemiol., June 1, 2001; 153(11): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. McKean-Cowdin, H. S. Feigelson, M. C. Pike, G. A. Coetzee, L. N. Kolonel, and B. E. Henderson Risk of Endometrial Cancer and Estrogen Replacement Therapy History by CYP17 Genotype Cancer Res., February 1, 2001; 61(3): 848 - 849. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Foca, G.E. Rice, M.A. Quinn, and E.K. Moses Identification and partial characterization of differentially expressed mRNAs in normal human endometria and endometrial carcinomas by differential display RT-PCR Mol. Hum. Reprod., August 1, 2000; 6(8): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Henderson and H. S. Feigelson Hormonal carcinogenesis Carcinogenesis, March 1, 2000; 21(3): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Lee, A. T.M. Verhoeven, and P. G. Rose Endometrial Carcinoma N. Engl. J. Med., May 8, 1997; 336(19): 1388 - 1389. [Full Text]
|
|